Qianyi Lu

CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer

Kai Zhang, Ruoxi Hong, Kaping Lee et al. · Cancer Letters · 2019 · 47 citations

Medicine, Oncology, Pharmacology +14

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population

Liye Wang, Qinglian Zhai, Qianyi Lu et al. · Annals of Medicine · 2021 · 31 citations · Full text

Medicine, Genetics, Oncology +15

Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast

Peng Sun, Zaixuan Zhong, Qianyi Lu et al. · Modern Pathology · 2020 · 30 citations

Medicine, Oncology, Pathology +15

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

Ruoxi Hong, Wen Xia, Kaping Lee et al. · Cancer Communications · 2021 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer

Qianyi Lu, Wen Xia, Kaping Lee et al. · The Oncologist · 2019 · 25 citations · Full text

Medicine, Oncology, Pharmacology +15